Literature DB >> 11986671

HIV preferentially infects HIV-specific CD4+ T cells.

Daniel C Douek1, Jason M Brenchley, Michael R Betts, David R Ambrozak, Brenna J Hill, Yukari Okamoto, Joseph P Casazza, Janaki Kuruppu, Kevin Kunstman, Steven Wolinsky, Zvi Grossman, Mark Dybul, Annette Oxenius, David A Price, Mark Connors, Richard A Koup.   

Abstract

HIV infection is associated with the progressive loss of CD4(+) T cells through their destruction or decreased production. A central, yet unresolved issue of HIV disease is the mechanism for this loss, and in particular whether HIV-specific CD4(+) T cells are preferentially affected. Here we show that HIV-specific memory CD4(+) T cells in infected individuals contain more HIV viral DNA than other memory CD4(+) T cells, at all stages of HIV disease. Additionally, following viral rebound during interruption of antiretroviral therapy, the frequency of HIV viral DNA in the HIV-specific pool of memory CD4(+) T cells increases to a greater extent than in memory CD4(+) T cells of other specificities. These findings show that HIV-specific CD4(+) T cells are preferentially infected by HIV in vivo. This provides a potential mechanism to explain the loss of HIV-specific CD4(+) T-cell responses, and consequently the loss of immunological control of HIV replication. Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986671     DOI: 10.1038/417095a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  522 in total

1.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Expression of CXCR4 on feline peripheral blood mononuclear cells: effect of feline immunodeficiency virus infection.

Authors:  Brian J Willett; Celia A Cannon; Margaret J Hosie
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load.

Authors:  Annetie Oxenius; Andrew K Sewell; Sara J Dawson; Huldrych F Günthard; Marek Fischer; Geraldine M Gillespie; Sarah L Rowland-Jones; Catherine Fagard; Bernard Hirschel; Rodney E Phillips; David A Price
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

4.  Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.

Authors:  Elizabeth Connick; Ronald J Bosch; Evgenia Aga; Rick Schlichtemeier; Lisa M Demeter; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

5.  Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Authors:  Gurvinder Kaur; Michael Tuen; Diana Virland; Sandra Cohen; Narinder K Mehra; Christian Münz; Sayed Abdelwahab; Alfredo Garzino-Demo; Catarina E Hioe
Journal:  Virology       Date:  2007-09-04       Impact factor: 3.616

6.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Harnessing CD4⁺ T cell responses in HIV vaccine development.

Authors:  Hendrik Streeck; M Patricia D'Souza; Dan R Littman; Shane Crotty
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

9.  Turnover of lymphocytes and conceptual paradigms in HIV infection.

Authors:  Guido Silvestri; Mark B Feinberg
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.